NOVEL MEDICINES FOR THE TREATMENT OF ARTERIAL HYPERTENSION, CHRONIC HEART FAILURE, RENAL FAILURE AND, IN GENERAL, CONDITIONS CAUSING HYDROSODED RETENTION.

摘要

The novel drug comprises, firstly, at least one atriopeptidase inhibitor, and preferably, sinorphan, an acetorphan enantiomer (S), and at least one calcic antagonist, preferably nifedipin.